Emmaus gains marketing authorisation for sickle cell treatment in Oman

Emmaus Life Sciences has received marketing authorisation for Endari (L-glutamine oral powder) in Oman for sickle cell disease.

Jul 15, 2023 - 20:00

Emmaus gains marketing authorisation for sickle cell treatment in Oman

Emmaus Life Sciences has received marketing authorisation for Endari (L-glutamine oral powder) in Oman for sickle cell disease.

Read the original article

Tags:

Previous Article

Health Canada approves AstraZeneca-Merck’s prostate cancer therapy

Incyte’s Opzelura Meets Primary Endpoint in Eczema Trial, but Safety Concerns Pe...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Out with the old, in with the new: Decoding biosimilar access with VPAG

Out with the old, in with the new: Decoding biosimilar ...

Jan 31, 2024

After outcry, UnitedHealthcare softens prior authorization policy for colonoscopies

After outcry, UnitedHealthcare softens prior authorizat...

Jun 2, 2023

STAT+: Raleigh-Durham challenges Boston as biomanufacturing hub of the future

STAT+: Raleigh-Durham challenges Boston as biomanufactu...

Feb 1, 2024